Mablink Bioscience S.A.S.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mablink Bioscience S.A.S. - overview
Established
2018
Location
Lyon, -, France
Primary Industry
Biotechnology
About
Based in Lyon, France and founded in 2018, Mablink Bioscience S. A. S. operates as a biotechnology company that focuses on developing drug therapies for cancer.
The company was founded by CEO Jean-Guillaume Lafay and CSO Warren Viricel. In April 2021, Mablink Bioscience raised EUR 4 million (USD 4. 83 million) in Seed funding from Elaia Partners, Groupe Crédit Agricole, and Simba Santé. Mablink Bioscience provides PSARlink™ is the company’s patented ADC platform that focuses on hydrophilic drug-linker and improvement of pharmacological properties.
The company plans to use its proceeds from seed funding to move forward with its ADC (Antibody-Drug Conjugates) pipeline.
Current Investors
Elaia Partners, Groupe Crédit Agricole, Pertinence Invest
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.mablink.com
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.